Literature DB >> 7014783

Studies in man with cold-recombinant influenza virus (H1N1) live vaccines.

P Reeve, B Gerendas, A Moritz, E Liehl, C Kunz, H Hofmann, H F Maassab.   

Abstract

Two cold-recombinant influenza A (H1N1) viruses were tested in several groups of human volunteers. Only minor clinical symptoms were seen and no febrile reactions occurred. With serologically primed individuals virus shedding was low, but a high proportion showed rises in serum antibody levels after vaccination and mean titres were high. With serologically unprimed volunteers shedding was high, about 75% yielding viruses but only at low titres and for a short duration. No revertant viruses were found and there was no evidence of transmission to potentially susceptible individuals housed in close contact to the vaccinees. Serum antibody responses with unprimed volunteers were, however, low. Only about one half showed increases in serum antibody titres after vaccination and mean titres were low. Nevertheless, challenge with live attenuated virus indicated a high degree of protection based on virological evidence of infection.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7014783     DOI: 10.1002/jmv.1890060110

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

Review 1.  Mucosal vaccines for the prevention of influenza.

Authors:  R L Clancy
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

2.  Epidemic influenza in Greater London.

Authors:  C C Spicer; C J Lawrence
Journal:  J Hyg (Lond)       Date:  1984-08

3.  Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus.

Authors:  M L Clements; S O'Donnell; M M Levine; R M Chanock; B R Murphy
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

4.  Recombinant cold-adapted attenuated influenza A vaccines for use in children: reactogenicity and antigenic activity of cold-adapted recombinants and analysis of isolates from the vaccinees.

Authors:  G I Alexandrova; F I Polezhaev; G N Budilovsky; L M Garmashova; N A Topuria; A Y Egorov; Y R Romejko-Gurko; T A Koval; K V Lisovskaya; A I Klimov
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

5.  A promoter mutation in the haemagglutinin segment of influenza A virus generates an effective candidate live attenuated vaccine.

Authors:  Ruth Harvey; Rachel E Johnson; Kirsty MacLellan-Gibson; James S Robertson; Othmar G Engelhardt
Journal:  Influenza Other Respir Viruses       Date:  2014-08-02       Impact factor: 4.380

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.